Počki (Apr 2018)
Effective treatment and prevention of recurrent urinary tract infections by using Cysto-aurin®, a Solidago virgaurea preparation
Abstract
We conducted a study of clinical and laboratory efficacy, as well as evaluated the effect on the quality of life of intermittent therapy with Cysto-aurin drug in 96 patients with recurrent urinary tract infection (UTI). After receiving an informed consent, the patients were divided into three statistically homogeneous groups. During the treatment, in all groups we used the strategy of behavioral therapy and postcoital prevention. Patients of group A additionally received Cysto-aurin 1 tablet qid by courses of 15 days in raw each month for 6 months, group B — the same drug for 2 tablets bid for 15 days in raw each month for 6 months, group C (comparison group) did not receive any special therapy. During the study, the data were obtained indicating a reliable decrease in the number of UTI relapses in groups A and B by 92.3 and 73.3 % within 6 months of treatment, depending on the frequency of drug administration. Analysis of the influence of the study drug on laboratory manifestations of recurrent UTI showed a positive effect of the intermittent treatment regimen on pyuria, a reduction in pro-inflammatory activity, and a statistically significant decrease of inflammation in the urinary system. Leukocyturia reduction in patients taking the drug was 73.4 and 44.6 %, i.e. 3.7 and 1.8 times lower than baseline, respectively. There was no statistically significant dynamics during the treatment among the patients of group C. A discrete and quantitative assessment of the impact of study drug on bacteriuria showed a clinically and statistically significant bacteriostatic effect of Cysto-aurin, both during the drug treatment in groups A and B (reduction by 41.0 and 27.6 %, respectively) and the prospective 6-month follow-up (by 30.3 and 18.0 %, respectively), which is an important confirmation of the effect of the drug on the microbial persistence in the urinary system. While structuring the antibacterial effect against clinically significant uropathogens, it was confirmed the reduction of E.coli strains by 61.1 and 31.9 %, Klebsiella pneumoniae — by 33.1 and 17.1 %, P.mirabilis — by 19.1 and 12.9 %, P.aeruginosa — by 21.1 and 14.1 %, Candida spp. — by 19.4 and 14.5 %, respectively. Evaluation of the effect of the study drug on the severity of recurrent chronic cystitis symptoms (UTI Symptoms Assessment) showed a significant decrease in the severity of key clinical symptomatic complexes of recurrent UTI: frequency (by 48.3 % in both groups), urgency (59.8 and 30.1 %), pain and burning (42.6 and 30.2 %), incomplete emptying of the bladder (53.8 and 30.9 %), as well as the integral indicator of clinical manifestations of pathology (24.7 and 39.2 %, respectively). The dynamics of health-related quality of life indicators (Short Form-36 score) when taking the study drug demonstrated a statistically significant induction of key quality-of-life domains for patients with recurrent UTI: mental health (33.4 vs. 32.5 %) and cumulative overall quality of life (19.6 against 14.6 %, respectively).
Keywords
